| 摘要 |
The present invention provides a compound comprising a helminth-derived glycan and/or glycoconjugate thereof (e.g., a compound comprising a Lewisx antigen (e.g., LNFPIII), a non-Lewisx antigen (e.g., LNnT, LDN, and LDN derivatives), or a mixture of Lewisx and non-Lewisx antigens (e.g., SEA)), useful as a therapeutic compound for treating or preventing diseases associated with fat accumulation in the liver. The compounds of the invention are useful for treating or preventing the development of a fatty liver disease in a subject that has the disease or is at risk of developing the disease, and inhibiting lipogenesis in hepatocytes. The invention also provides methods of regulating the Erk-c-fos/AP-1-FXRα signalling pathway by administering a compound comprising a helminth-derived glycan and/or glycoconjugate thereof to a subject with a fatty liver disease, or contacting a hepatocyte with a compound comprising a helminth-derived glycan and/or glycoconjugate thereof. |
